EUVIMEDEUVIMED entdecken
Open Access

TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer

Muhammad Jameel Mughal, Yi Zhang, Zhuqing Li, Shuyan Zhou, Changmin Peng, Ya-Qin Zhang, Edward Seto, Min Shen, Matthew D Hall, Wenge Zhu

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2024.217356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Muhammad Jameel Mughal und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Medicine, GWU Cancer Center, George Washington University School of Medicine and Health Sciences, Washington…. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase 4, Piperazines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the predominant malignancy with the majority of cases are characterized as HR+/HER2-subtype. Although cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have shown remarkable efficacy in treating this subtype when combined with endocrine therapy, the development of resistance to these inhibitors remains a significant clinical obstacle. Hence, there is an urgent need to explore innovative therapies and decipher the underlying mechanisms of resistance to CDK4/6i. In this study, we employed quantitative high-throughput combination screening (qHTCS) and genomics/proteomics approaches to uncover the molecular mechanisms driving resistance to CDK4/6i (palbociclib) in breast cancer. The comprehensive analyses revealed DDR1 as a potential factor implicated in mediating resistance to CDK4/6i. Specifically, DDR1 inhibition in combination with palbociclib exhibited remarkable synergistic effects, reducing cell survival signaling and promoting apoptosis in resistant cells. In-vivo xenograft model further validated the synergistic effects, showing a significant reduction in the resistant tumor growth. Exploration into DDR1 activation uncovered TFAP2C as a key transcription factor regulating DDR1 expression in palbociclib resistant cells and inhibition of TFAP2C re-sensitized resistant cells to palbociclib. Gene set enrichment analysis (GSEA) in the NeoPalAna trial demonstrated a significant enrichment of the TFAP2C-DDR1 gene set from patitens after palbociclib treatment, suggesting the possible activation of the TFAP2C-DDR1 axis following palbociclib exposure. Overall, this study provides crucial insights into the novel molecular landscape of palbociclib resistance in breast cancer, suggesting TFAP2C-DDR1 axis inhibition as a promising strategy to overcome resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsDrug Resistance, NeoplasmCyclin-Dependent Kinase 4PiperazinesPyridinesCyclin-Dependent Kinase 6Transcription Factor AP-2Xenograft Model Antitumor AssaysProtein Kinase InhibitorsDiscoidin Domain Receptor 1HumansFemaleAnimalsMiceCell Line, TumorApoptosisCell ProliferationMice, NudeGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Breast cancerCDK4/6 inhibitorsDDR1ResistanceTFAP2C

Substanzen

Cyclin-Dependent Kinase 4PiperazinespalbociclibPyridinesCyclin-Dependent Kinase 6Transcription Factor AP-2Protein Kinase InhibitorsDiscoidin Domain Receptor 1DDR1 protein, humanCDK4 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Medicine, GWU Cancer Center, George Washington University School of Medicine and Health Sciences, Washington, DC, 20037, USA.
  • Early Translation Branch, Division of Preclinical Innovation, National Center for Translational Sciences (NCATS), National Institutes of Health (NIH), Rockville, MD, 20850, USA.
  • Department of Biochemistry and Molecular Medicine, GWU Cancer Center, George Washington University School of Medicine and Health Sciences, Washington, DC, 20037, USA. Electronic address: wz6812@gwu.edu.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • National Center for Advancing Translational Sciences
  • George Washington University

Zitieren

APA

Mughal, M. J., Zhang, Y., Li, Z., Zhou, S., Peng, C., Zhang, Y. Q., Seto, E., Shen, M., Hall, M. D., & Zhu, W. (2025). TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217356

Vancouver

Mughal MJ, Zhang Y, Li Z, Zhou S, Peng C, Zhang YQ, et al. TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer. Cancer Letters. 2025. doi:10.1016/j.canlet.2024.217356

BibTeX
@article{Mughal2025,
  author = {Mughal, Muhammad Jameel and Zhang, Yi and Li, Zhuqing and Zhou, Shuyan and Peng, Changmin and Zhang, Ya-Qin and Seto, Edward and Shen, Min and Hall, Matthew D and Zhu, Wenge},
  title = {TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2024.217356}
}
Kostenlos starten →